Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Listed Wholesalers Increased Hiring of New Graduates: PJ Survey
May 17, 2004
- Annual Business Results
May 17, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 3, 2004
- BUSINESS NEWS IN BRIEF
May 3, 2004
- Results of Study on Combination of PTX, CBDCA Reported
May 3, 2004
- BUSINESS NEWS IN BRIEF
May 3, 2004
- Zyrtec Significantly Reduces Symptoms of Pollinosis
May 3, 2004
- WEBSITE NEWS
May 3, 2004
- Technomics Analyzes Drugs Discontinued in Development 1985-2003
May 3, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
May 3, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
May 3, 2004
- 6 New Drugs Including Visdyne Added to the NHI Price List
May 3, 2004
- PRESS SEMINAR
May 3, 2004
- REGULATORY NEWS IN BRIEF
May 3, 2004
- BULLETIN
May 3, 2004
- JRCS to Build Large-scale Clinical Trial Network
May 3, 2004
- OTC NEWS IN BRIEF
May 3, 2004
- Terumo Aims for 10th Consecutive Year of Growth in FY2004
May 3, 2004
- MEDICAL DEVICE NEWS IN BRIEF
May 3, 2004
- DIAGNOSTIC NEWS IN BRIEF
May 3, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…